GlassScriptPhysician profile
Mojdeh Tabibian
NPI 1558845792
$7,940.99
in general payments reported to CMS, 2019-2025
24 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.20 · 2022: $547 · 2023: $2,064 · 2024: $2,952 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,821 · Education: $541 · Travel and Lodging: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,820.52 |
| Education | $541.45 |
| Travel and Lodging | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.96 | 2022-2025 | |
| Genzyme Corporation | $1,079.12 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $874.69 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $764.02 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $754.31 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $609.59 | 2023-2025 | Zoryve |
| Incyte Corporation | $464.38 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $423.10 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $372.82 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $285.19 | 2024 | Vtama |
| Amgen INC. | $280.50 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $140.10 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $122.41 | 2022-2025 | |
| Galderma Laboratories, L.P. | $103.20 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $93.21 | 2024-2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $90.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.96 | 2022-2025 | |
| Journey Medical Corporation | $47.72 | 2025 | |
| Leo Pharma INC. | $47.60 | 2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.65 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Astrazeneca Pharmaceuticals LP | $19.94 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.84 | 2025 | Ycanth |
| Mimedx Group, INC. | $15.53 | 2025 | |
| Tactile Systems Technology INC | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mojdeh Tabibian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.